Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
favipiravir + AV5125
- Development stage
- Unknown
- Lead developer
- Viriom
- Modality
- Small Molecules
01
Overview
Favipiravir + AV5125 is a combination therapy being developed by Viriom for the treatment of seasonal and pandemic influenza. The combination consists of two small molecules that target the viral RNA polymerase complex. Favipiravir is a well-established viral RNA polymerase inhibitor that acts as a prodrug; it is metabolized into favipiravir-ribofuranosyl-5'-triphosphate, a nucleoside analogue that inhibits viral RNA-dependent RNA polymerase (RdRp). AV5125 is a complementary antiviral agent that also targets the viral RNA polymerase, intended to enhance the potency of the treatment and address challenges related to drug resistance. The therapeutic combination is currently in Phase 1 clinical development.
- Other names
- Favipiravir & AV5125Favipiravir + AV5125
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)Influenza A virus RNA-directed RNA polymerase complex
Beyond the preview
Go deeper on favipiravir + AV5125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on favipiravir + AV5125.